

 AETNA BETTER HEALTH® OF FLORIDA 261 N. University Drive Plantation, FL 33324 www.AetnaBetterHealth.com/Florida	Date:	September 11, 2023
	Purpose:	Formulary Change: Alert providers that Humatrope being added to Florida Healthy Kids preferred drug list
	Subject:	Humatrope added to FHK preferred drug list
	Products:	Florida Healthy Kids
	From:	<u>Pharmacy</u>

Aetna Better Health® of Florida

Humatrope being added to Florida Healthy Kids preferred drug list

Dear Providers,

Effective 10/1/2023, Humatrope will be added to the Florida Healthy Kids preferred drug list (PDL). This means that there will be two preferred growth hormone agents moving forward: Norditropin and Humatrope.

Norditropin and Humatrope require PA for approval. For members to get a non-preferred growth hormone product after this time, they will need to try and fail BOTH Norditropin and Humatrope. There has been a growth hormone shortage since November 2022. The goal of adding Humatrope is to have another preferred formulary option available to FHK members. Once temporary PAs for non-preferred growth hormone drugs start to expire, FHK members will need to switch to Norditropin or Humatrope. If there is some reason that a member cannot use the preferred drugs, this must be documented and submitted with a PA request.

Note: this change applies only to Florida Healthy Kids. Medicaid will continue to follow the Agency for Healthcare Administration (AHCA) preferred drug list and criteria.

We appreciate the excellent care you provide to our members. As always, please don't hesitate to contact our ABHFL Provider Services line if you have any questions at:

Phone: MMA: [1-800-441-5501](tel:1-800-441-5501) TTY (711)

LTC: [1-844-645-7371](tel:1-844-645-7371) TTY (711)

FHK: [1-844-528-5815](tel:1-844-528-5815) TTY (711)

Email: FLMedicaidProviderRelations@aetna.com

Thank you,

Aetna Better Health of Florida

www.aetnabetterhealth.com/florida

CONFIDENTIALITY NOTICE: This message is intended only for the use of the individual or entity to which it is addressed and may contain confidential and proprietary information. If you are not the intended recipient of the employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this communication is prohibited. If you received this communication in error, please notify the sender at the phone number above. **NOTICE TO RECIPIENT(S) OF INFORMATION:** Information disclosed to you pertaining to alcohol or drug abuse treatment is protected by federal confidentiality rules (42 CFR Part 2), which prohibit any further disclosure of this information by you without express written consent of the person to whom it pertains or as otherwise permitted by 42 CFR Part 2. A general authorization for the release of medical or other information is NOT sufficient for this purpose. The federal rules restrict any use of the information to criminally investigate or prosecute any alcohol or drug abuse patient.